These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An overview of the new frontiers in the treatment of atherogenic dyslipidemias. Rached FH; Chapman MJ; Kontush A Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469 [TBL] [Abstract][Full Text] [Related]
5. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Gaudet D; Drouin-Chartier JP; Couture P Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054 [TBL] [Abstract][Full Text] [Related]
6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
9. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
10. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia. Tziomalos K Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622 [TBL] [Abstract][Full Text] [Related]
11. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404 [TBL] [Abstract][Full Text] [Related]
12. Emerging options in the treatment of dyslipidemias: a bright future? Florentin M; Liberopoulos EN; Mikhailidis DP; Elisaf MS Expert Opin Emerg Drugs; 2011 Jun; 16(2):247-70. PubMed ID: 21323473 [TBL] [Abstract][Full Text] [Related]
13. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk. Shapiro MD; Fazio S Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970 [TBL] [Abstract][Full Text] [Related]
14. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]